X

Syngene International Q4FY23 results out, revenue rises by 31%

Syngene (established in 1993) as a Biocon subsidiary is India’s first Contract Research Organization (CRO) which expanded later to be an integrated service provider offering end-to-end drug discovery, development, and manufacturing services on a single platform (CRAMS). Total research & manufacturing infrastructure for the company is spread across 1.9 million square feet across locations.

  • Syngene reported Total revenue for Q4 FY23 of ₹994 Crore, up from ₹759 Crore year on year, a growth of 31%.
  • Total Expenses for Q4 FY23 of ₹786 Crore up, from ₹593 Crore year on year, a growth of 32%.
  • Consolidated Net Profit of ₹179 Crore, up 21% from ₹147 Crore in the same quarter of the previous year.
  • The Earnings per Share is ₹4.43, up 21% from ₹3.67 in the same quarter of the previous year.
Related Post